Login to Your Account

Lion Roars on Long-Term Metastatic Melanoma Data

By Marie Powers
Staff Writer

Monday, September 30, 2013
Little Lion Biotechnologies Inc., the surviving entity of a merger earlier this year with Genesis Biopharma Inc., reported promising long-term findings from a Phase II trial in Stage IV metastatic melanoma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription